Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gaurav Gaiha
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gilead Sciences, Inc.
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Gaiha’s spouse is an employee of Gilead Sciences, Inc.; as an employee, she receives cash compensation and holds stock in the company, valuing approximately (b)(4). Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of HIV/AIDS, liver diseases, hematology/oncology, cardiovascular, and inflammation/respiratory. The research involves the application of a new approach known as structure-based network analysis to evaluate whether predicted epitopes can serve as targets for inclusion in a rationally designed, therapeutic CTL-based vaccine for HIV-1. The research and the company have an overlapping interest in the prevention of HIV and, if the research is successful, the company may have an interest in the resulting IP. The Partners Committee on Outside Activities reviewed the financial interest in connection with the research and determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research. The committee determined that the conflict could be managed with the implementation of an FCOI management plan.
Leveraging CTLs targeting highly networked epitopes to suppress the latent HIV-1 reservoir
Project Narrative The proposed research is relevant to public health due to the significant and unmet need of an HIV-1 cure. The project will apply a new approach known as structure-based network analysis and evaluate whether predicted epitopes can serve as targets for inclusion in a rationally designed, therapeutic CTL-based vaccine for HIV-1. Thus, the proposed work is relevant to the NIH's mission to seek and apply knowledge to lengthen life and reduce illness. �
Filed on April 29, 2019.
Tell us what you know about Gaurav Gaiha's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Gaurav Gaiha filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Gaurav Gaiha | Massachusetts General Hospital | Conflict of Interest | Gilead Sciences, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.